New insights into statin-intolerance: biopsychosocial differences, medication beliefs, trust in healthcare and treatment decisions in statin-intolerant versus statin-tolerant patients

Clicks: 3
ID: 325611
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #134 of 194 articles by views in european journal of preventive cardiology

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 194 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Abstract
AIMS: This study examined biopsychosocial differences between statin-intolerant and statin-tolerant patients, including their medication beliefs, healthcare trust and influential factors for treatment decisions. METHODS: A cross-sectional survey study was conducted among current and former statin-users. Data on demographics, comorbidities, psychosocial factors, medication beliefs, trust in healthcare and factors influencing treatment decisions was collected. Statin-intolerance was classified according to the National Lipid Association definition. RESULTS: Of 1,019 participants (median 66 years, 59% men), 178 (17%) were classified as statin-intolerant. In a multivariable binary logistic regression model (odds ratio, 95% confidence interval), the demographic and biological factors female sex (1.52, 1.05-2.19), atherosclerotic cardiovascular disease diagnosis (1.97, 1.39-2.80), musculoskeletal disease diagnosis (1.93, 1.17-3.15) and gastro-intestinal disease diagnosis (1.92, 1.01-3.52) were associated with statin-intolerance, but not psychosocial factors. Statin-intolerant vs statin-tolerant respondents held a more negative general view of medication (overuse 11 [9-13] vs. 10 [8-12], p=0.03; harms 9 [8-11] vs. 8 [7-10], p=0.02) and of statins (necessity 13 [11-16] vs. 15 [13-17], p<0.001; concerns 13 [11-16] vs. 11 [10-13], p<0.001), reported lower trust in healthcare professionals (42 [37-46] vs. 44 [38-48], p=0.02) and prioritized experienced side-effects (91 [76-99] vs. 45 [10-70], p<0.001) over benefits (effect on lipid-levels 65 [41-85] vs. 77 [50-93], p<0.001) in their statin-treatment decision. CONCLUSIONS: Statin-intolerant patients differ from statin-tolerant patients in demographic and biological characteristics, medication beliefs and healthcare trust. They prioritize negative factors in treatment decisions, underscoring importance of early communication on statin benefits and alternative symptom causes.
Reference Key
openalex_W7203673249 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Ruben J M Mijnster, Neivyn Shaheen, Wim J R Rietdijk, Fabrice M A C Martens, Remy Bemelmans, Inge Merkelbach, P Hugo M van der Kuy, Melvin Lafeber, Jeanine E Roeters van Lennep
Journal european journal of preventive cardiology
Year 2026
DOI
10.1093/eurjpc/zwag415
URL
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

No comments yet. Be the first to comment on this article.